{"id":1067922,"date":"2020-12-31T01:53:08","date_gmt":"2020-12-31T06:53:08","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/chi-med-announces-the-nmpa-approval-of-surufatinib-sulanda-in-china-for-non-pancreatic-neuroendocrine-tumors\/"},"modified":"2024-08-18T11:40:57","modified_gmt":"2024-08-18T15:40:57","slug":"chi-med-announces-the-nmpa-approval-of-surufatinib-sulanda-in-china-for-non-pancreatic-neuroendocrine-tumors","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/chi-med-announces-the-nmpa-approval-of-surufatinib-sulanda-in-china-for-non-pancreatic-neuroendocrine-tumors.php","title":{"rendered":"Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda\u00ae in China) for Non-Pancreatic Neuroendocrine Tumors"},"content":{"rendered":"<p><![CDATA[\u2013 Sulanda\u00ae is Chi-Med\u2019s first oncology drug brought to market without a partnership and the company\u2019s second oncology drug approved in\u00a0China\u00a0\u2013]]><\/p>\n<p>Here is the original post:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"http:\/\/www.globenewswire.com\/news-release\/2020\/12\/30\/2151651\/0\/en\/Chi-Med-Announces-the-NMPA-Approval-of-Surufatinib-Sulanda-in-China-for-Non-Pancreatic-Neuroendocrine-Tumors.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda\u00ae in China) for Non-Pancreatic Neuroendocrine Tumors\">Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda\u00ae in China) for Non-Pancreatic Neuroendocrine Tumors<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Here is the original post: Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda\u00ae in China) for Non-Pancreatic Neuroendocrine Tumors <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/chi-med-announces-the-nmpa-approval-of-surufatinib-sulanda-in-china-for-non-pancreatic-neuroendocrine-tumors.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1067922","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1067922"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1067922"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1067922\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1067922"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1067922"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1067922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}